I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Dianthus Therapeutics with an unchanged $125 price target. The decision is supported by the company's strong balance sheet, featuring approximately $1.2 billion in cash extending its runway to 2030, eliminating near-term financing risks. Additionally, the newly disclosed DNTH312 pipeline asset is viewed as strategically important due to its best-in-class potential and broad applicability in neuromuscular and autoimmune diseases.
Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Dianthus Therapeutics and keeping the price target at $125.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Rami Katkhuda has given his Buy rating due to a combination of factors, including Dianthus’s exceptionally strong balance sheet and extended cash runway. With roughly $1.2B in cash and equivalents projected to fund operations into 2030, the company is positioned to advance its pipeline without near‑term financing risk, supporting the unchanged $125 price target.
He also views the newly disclosed DNTH312 as a strategically important asset that reinforces the growth story. DNTH312’s bifunctional design—combining potent classical complement inhibition with BAFF/APRIL targeting—offers best‑in‑class potential and broad neuromuscular and autoimmune applicability, which, together with Claseprubart’s ongoing development, underpins his expectation for meaningful long‑term value creation in DNTH.